对于克罗恩病的吸烟者而言,戒烟干预措施的有效性:系统审查
Sahar Nasr1, Ilyess Nsiri1, Manel Ben Fredj2
1Gastroenterology Department, University of Tunis, Tunisia.
Future science OA
|July 24, 2023
概括
对于克罗恩病的戒烟干预措施
科学领域:
- 胃肠病学和肝病学
- 公共卫生 公共卫生
- 成 药物 药物 药物 药物
背景情况:
- 戒烟 (SC) 对于改善克罗恩病 (CD) 患者的治疗结果至关重要.
- 确定CD的有效SC干预措施对于患者管理至关重要.
- 关于SC干预在CD患者的疗效的证据需要系统审查.
研究的目的:
- 总结有关在克罗恩病患者中戒烟干预措施有效性的现有证据.
- 评估成功率,并确定成功戒烟的预测因素.
主要方法:
- 在PubMed,谷歌学者和科克兰图书馆数据库中进行系统的文献搜索.
- 纳入标准侧重于报告克罗恩病患者戒烟干预措施的研究.
- 数据提取包括研究样本大小,禁欲率和干预成功预测指标.
主要成果:
- 五项研究符合纳入标准,样本大小从17名患者到474名患者.
- 报告的戒烟禁欲率从14.8%到42%不等,其中四项研究显示率≤25%.
- 在三个研究中,干预组与对照组相比没有观察到统计学上显著的更高的戒烟率;没有确定成功的预测因素.
结论:
- 目前的证据表明,在克罗恩病患者中,现有的戒烟干预措施的有效性有限.
- 需要进一步的研究来开发和评估为这个特定的患者群体量身定制的SC干预措施.
- 对于克罗恩病患者,建议立即实施和评估专门的SC计划.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...


